Watch the latest episode of focusIR Fireside Chats: Why Edinburgh Investment Trust Is Backing Turnaround Stocks for 2026 Growth. View here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksReabold Resources Regulatory News (RBD)

Share Price Information for Reabold Resources (RBD)

Share Price is delayed by 15 minutes
Get Live Data
82.50    1.50 (1.85%)
Bid:
81.00
Ask:
84.00
Spread: 3.00 (3.704%)
Market Cap: £11.96m
RBD Live PriceLast checked at - London Stock Exchange

Intraday Reabold Resources Share Chart

Contract Gain

14 Feb 2006 07:01

Adventis Group PLC14 February 2006 For release 07.00am 14 February 2006 Adventis Group plc Contract Gain Adventis, the specialist multimedia marketing and advertising agency, announcesthat Affiniti (UK) Ltd, its Bucks-based healthcare agency has been awarded theZanidip account following a three-way pitch. The contract, for an undisclosedamount, is now live. Zanidip (lercanidipine), a highly effective calcium blocker used by GP's tolower blood pressure in the treatment of hyper tension, was originally licensedout but the Italian multi-national pharmaceutical group Recordati S.p.A. has nowopened a UK marketing office and will henceforward market the drug itself. Highblood pressure is a problem most common in the elderly, related to poor controlof the working of the heart, and for kidney and liver diseases. Although Affiniti has been involved before in marketing the Zanidip brand,Recordati were looking for a completely fresh approach to move the productforward. Martin Symons, Recordati's UK General Manager, commented: "It was by no means aforegone conclusion for Affiniti - they had to perform on an even playing fieldagainst good competitors, but they came through very strongly. We look forwardto working with them to develop a strong campaign that will move Zanidip to itsrightful position in the marketplace." Affiniti has also won three other pitches against major league competition: - A major product launch for MabThera in severe rheumatoid arthritis for Roche - A major new European campaign in glaucoma for Allergan's Lumigan - A new campaign for Periostat, a dental root treatment for Alliance Said Affiniti's Managing Director, Stuart Tennant: "Across all these recentpitches we have been up against some of the UK's leading healthcare agencieswith big creative reputations - so we know we can compete at the top level. Weare continuing to build our team, our clients' brands - and a strong reputationof our own." - ENDS - Editor's Notes Adventis Group plc is an AIM listed, full service marketing and advertisingagency, providing services to the property, healthcare and financial servicesindustries. Through its six operating companies the company provides a complete range ofcommunication services, including corporate identity programmes, advertisingcampaigns, media planning & buying, literature, public relation, packaging,exhibitions, research and planning, interiors, signage and digital media. Adventis employs over 80 staff in London and the South East. www.adventis.co.uk Recordati is a European pharmaceutical group mainly dedicated to the research,development, manufacturing and marketing of pharmaceuticals. Headquartered inMilan, it has operations in France, Germany, Greece, Ireland, Italy, Spain,Switzerland, the United Kingdom and the United States. Recordati has been listedon the Italian Stock Exchange since 1984. www.recordati.com Enquiries: Affiniti (UK) LtdStuart Tennant, Managing Director 01494 775 213 Adventis Group plc Charles Phillpot, Chief Executive Officer 020 7034 4750 Seymour PierceJohn Depasquale 020 7107 8000 Binns & Co PR Ltd 020 7786 9600Peter Binns / 07768 392 582Annie Evangeli 07778 507 162 This information is provided by RNS The company news service from the London Stock Exchange
Date   Source Headline
4th Apr 20119:56 amRNSDirectorate Change
23rd Mar 20112:55 pmRNSNPA - termination of recognition
4th Mar 201111:38 amRNSChange of Registered Office
14th Feb 20117:00 amRNSDirectorate Change
27th Jan 20117:00 amRNSTrading Update
9th Nov 20107:00 amRNSDirectorate Change
15th Sep 20107:00 amRNSDirector Declaration
15th Sep 20107:00 amRNSInterim Results - half year ended 30 June 2010
18th Aug 20107:00 amRNSTrading Update
13th Aug 201012:25 pmRNSDirector/PDMR Shareholding
19th May 20104:01 pmRNSResult of AGM
19th May 20107:00 amRNSAGM Statement
5th May 201010:55 amRNSAnnual Report Published
30th Apr 20107:00 amRNSSettlement of Litigation
29th Apr 20101:30 pmRNSre RNS announcement
29th Apr 20107:00 amRNSSettlement of Litigation
29th Mar 20104:44 pmRNSDirectors' Dealings and Options Exercise
24th Mar 20107:00 amRNSFinal Results
2nd Feb 20107:00 amRNSAcquisition
29th Jan 20107:00 amRNSTrading Statement
16th Dec 200912:05 pmRNSHolding(s) in Company
19th Nov 20094:42 pmRNSHolding(s) in Company
12th Nov 20094:14 pmRNSHolding(s) in Company
12th Nov 20092:43 pmRNSHolding(s) in Company
11th Nov 20097:00 amRNSDirector/PDMR Shareholding
10th Nov 20092:23 pmRNSDirector/PDMR Shareholding
5th Nov 20097:00 amRNSPlacing
30th Sep 20097:00 amRNSInterim results
30th Jul 20097:00 amRNSTrading Update
3rd Jul 20095:35 pmRNSPayments of deferred and earn-out consideration
1st Jul 20094:48 pmRNSGrant of Share Options
3rd Jun 200912:53 pmRNSResult of AGM
3rd Jun 20097:00 amRNSAGM Statement
11th May 20095:04 pmRNSAnnual Report & Notice of AGM
15th Apr 20091:24 pmRNSHolding(s) in Company
15th Apr 200910:10 amRNSFinal Dividend
15th Apr 20097:00 amRNSFinal Results
12th Feb 20093:47 pmRNSDirector/PDMR Shareholding
29th Jan 20097:00 amRNSTrading Statement
21st Jan 20097:00 amRNSDirectorate Change
16th Jan 20093:09 pmRNSDirector/PDMR Shareholding
15th Dec 20084:01 pmRNSDirector/PDMR Shareholding
9th Dec 200812:32 pmRNSHolding(s) in Company
9th Dec 20089:34 amRNSDirector/PDMR Shareholding
8th Dec 20081:59 pmRNSDirector/PDMR Shareholding
3rd Dec 20087:00 amRNSTrading Statement
20th Nov 20087:00 amRNSDirectorate Change
27th Oct 20083:12 pmRNSTransaction in Own Shares
10th Oct 20084:45 pmRNSTransaction in Own Shares
2nd Oct 200811:01 amRNSTransaction in Own Shares

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.